CPLX2是一种新型瘤抑制剂,可改善质瘤的预后
Yuanbing Chen1, Jieling Ning2,3, Long Shu4,5
1Department of Neurosurgery, Third Xiangya Hospital, Central South University, 410008, Changsha, Hunan, China.
Journal of neuro-oncology
|March 1, 2024
概括
复合素-2 (CPLX2) 在质瘤中作为瘤抑制剂,这是中枢神经系统癌症. 它的下调与较高的质瘤等级相关,恢复CPLX2表达可能会改善患者的预后.
科学领域:
- 神经瘤学神经瘤学
- 癌症生物学 癌症生物学
- 分子诊断学 分子诊断学
背景情况:
- 质瘤是一种恶性中枢神经系统癌症,尽管正在进行生物标志物研究,但临床预后不佳.
- 了解新型瘤抑制剂对于改善质瘤患者的治疗结果至关重要.
研究的目的:
- 调查复合素-2 (CPLX2) 在质瘤中的作用.
- 阐明CPLX2在质瘤中的潜在瘤抑制功能背后的分子机制.
主要方法:
- 来自TCGA和CGGA数据库的质瘤患者数据中CPLX2表达的分析.
- 在68名质瘤患者中进行RT-qPCR验证.
- 卡普兰-梅尔生存分析.
- 在CPLX2倒置和过度表达模型的体外和体内研究.
主要成果:
- 在质瘤中,CPLX2的表达下调,与瘤等级相反相关.
- 较高的CPLX2表达与患者生存率的改善有关.
- 过度表达CPLX2会抑制质瘤细胞的生长,殖民地形成和瘤异种移植的发展.
- 抑制CPLX2可以促进质瘤细胞的增殖.
- 基因组丰富分析 (GSEA) 表明CPLX2通过缺氧和炎症途径影响质瘤恶性.
结论:
- 在质瘤中,CPLX2作为瘤抑制剂起作用.
- CPLX2有可能成为质瘤患者的预后生物标志物.
更多相关视频
10:58Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
Published on: February 22, 2015
12.9K
04:01Author Spotlight: Modeling Brain Tumors In Vivo Using Electroporation-Based Delivery of Plasmid DNA Representing Patient Mutation Signatures
Published on: June 23, 2023
1.7K
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
